IDH1 and neoplasm: Strikingly, long-term survivors from IDH1-R132H inhibition in combination with SOC and anti-PD-L1 immune checkpoint treatment group remained tumor-free post mIDH1 glioma rechallenging in the contralateral hemisphere, indicating the development of anti-mIDH1 glioma immunological memory (24).